Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Capsule Endoscopy

Capsule Endoscopy

Capsule endoscopy is a non-invasive diagnostic procedure that uses a small, wireless camera encased in a pill-sized capsule to capture images of the digestive tract.
The capsule is swallowed by the patient and travels naturally through the esophagus, stomach, and small and large intestines, transmitting images to a recording device worn by the patient.
This technique allows for visualization of areas of the gastrointestinal tract that are difficult to access with traditional endoscopic methods.
Capsule endoscopy is used to detect and diagnose a variety of conditions, including obscure gastrointestinal bleeding, Crohn's disease, small intestinal tumors, and other disorders.
The procedure is typically well-tolerated by patients and has a low risk of complications.
Optimizing capsule endoscopy research can be achieved through the use of AI-driven platforms like PubCompare.ai, which can help locate relevant protocols, identify the best products, and enhance reproducibility and accuracy in this important diagnostic field.

Most cited protocols related to «Capsule Endoscopy»

1
Standardizing Small Bowel Vascular Lesion Characterization

The multicenter French database CAD-CAP (Computer-assisted Diagnosis for Capsule endoscopy) was used. CAD-CAP is composed of 20,000 normal CE still frames and 6013 still frames of abnormal CE findings from third-generation SBCE system videos (Pillcam SB3 system, Medtronic), including 2946 vascular lesions
14
. The CG selected an initial set of 100 still frames of most common vascular lesion images seen in SBCE. Based on this image dataset and on their knowledge, the members of the CG categorized 5 different types of SB vascular lesions. For each type of SB vascular lesion, the CG selected 4 typical frames (with adequate mucosal visualization and brightness) and proposed a putative name and a semantic description, to be sent to the EG through an Internet-based questionnaire. At each round, and for each type of lesion, members of the EG were asked to rate proposals of the CG, on a numerical scale from 1 (strongly disagree) to 6 (strongly agree) (
Table 1), and to provide comments and suggestions for substantive revisions. After each round, all suggestions from EG respondents were used by the CG to improve names/descriptions.
Leenhardt R., Li C., Koulaouzidis A., Cavallaro F., Cholet F., Eliakim R., Fernandez-Urien I., Kopylov U., McAlindon M., Németh A., Plevris J.N., Rahmi G., Rondonotti E., Saurin J.C., Tontini G.E., Toth E., Yung D., Marteau P, & Dray X. (2019). Nomenclature and semantic description of vascular lesions in small bowel capsule endoscopy: an international Delphi consensus statement. Endoscopy International Open, 7(3), E372-E379.
Publication 2019
Blood Vessel Capsule Endoscopy Computer Assisted Diagnosis Mucous Membrane Reading Frames Vision
2
Celiac Disease Protocol Evaluating Larazotide

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Abdominal Pain Anti-Inflammatory Agents, Non-Steroidal Antibiotics Antibodies, Anti-Idiotypic Biological Assay Biopsy Capsule Endoscopy Celiac Disease Clinical Laboratory Services Diabetes Mellitus Diarrhea Disease, Chronic Dyspepsia Enteropathy-Associated T-Cell Lymphoma Feelings Galvanic Skin Response Gliadin Gluten Immunosuppressive Agents Inflammation Inflammatory Bowel Diseases Intestines larazotide acetate Malabsorption Syndrome Medical Devices Nausea Nervous System Disorder Patients Peptides Permeability Pharmaceutical Preparations Pregnancy Stomach Therapeutics
3
Capsule Endoscopy Examination Registry
A total of 2,914 CE examinations were enrolled in the capsule registry from October 2002 to September 2012. CEs were performed at 24 hospitals across Korea. Information including age, gender, reasons for CE, CE findings (small bowel lesions), CE diagnosis, method and quality of bowel preparation, complete examination, and retention was gathered by an Internet web site. Various CE instruments (PillCam SB1 and SB2, Given Imaging, Yokneam, Israel; MiroCam, IntroMedic Co., Ltd., Seoul, Korea; EndoCapsule, Olympus, Tokyo, Japan) were used.
The reasons for CE included OGIB, unexplained abdominal pain, chronic diarrhea, Crohn's disease, small bowel tumor, ulcerative colitis, Behcet's disease, ischemic enteritis, unknown origin of weight loss, cancer, and protein losing enteropathy. OGIB was defined as bleeding of unknown origin that persisted or recurred after an initial upper and lower gastrointestinal endoscopy with negative findings. In addition to cases of melena or hematochezia, persistent iron deficiency anemia or positive stool occult blood with negative findings on the initial endoscopy were also considered OGIB. CE findings and diagnoses were described based upon capsule endoscopy structured terminology.
Before the CE study, each patient received bowel preparation according to clinician preference. The various methods of bowel preparation included nothing per os (NPO) for 12 hours or use of purgative agents such as 2 or 4 L sodium phosphate (NaP) or polyethylene glycol (PEG) conducted in each hospital. Independent examiners categorized the quality of bowel preparation for CE. The quality the preparations were categorized as follows: excellent, visualization of ≥90% of the mucosa, no or minimal fluid, debris, and bubbles (Fig. 1A); good, visualization of ≥90% of the mucosa, mild fluid, debris, and bubbles (Fig. 1B); fair, visualization of <90% of the mucosa, moderate fluid, debris, and bubbles (Fig. 1C); poor, visualization of <80% of the mucosa, excessive fluid, debris, and bubbles (Fig. 1D).9 (link)10 (link)
The overall incomplete and retention rates as well as the factors affecting completion and CE retention were investigated. Completion was defined as the capsule reaching the cecum during the recording time. Capsule retention was defined as the capsule remaining in the digestive tract for more than 2 weeks.
Lim Y.J., Lee O.Y., Jeen Y.T., Lim C.Y., Cheung D.Y., Cheon J.H., Ye B.D., Song H.J., Kim J.S., Do J.H., Lee K.J., Shim K.N., Chang D.K., Park C.H., Jang B.I., Moon J.S., Chun H.J., Choi M.G, & Kim J.O. (2015). Indications for Detection, Completion, and Retention Rates of Small Bowel Capsule Endoscopy Based on the 10-Year Data from the Korean Capsule Endoscopy Registry. Clinical Endoscopy, 48(5), 399-404.
Publication 2015
Abdominal Pain Behcet Syndrome Capsule Capsule Endoscopy Cathartics Cecum Crohn Disease Diagnosis Diarrhea Edema Endoscopy, Gastrointestinal Enteritis Fecal Occult Blood Test Gastrointestinal Tract Gender Hematochezia Intestinal Neoplasms Intestines Intestines, Small Iron Deficiency Anemia Malignant Neoplasms Melena Mucous Membrane Neoplasms Patients Physical Examination Polyethylene Glycols Protein-Losing Enteropathies Retention (Psychology) sodium phosphate Ulcerative Colitis
4
Quiescent Crohn's Disease with IBS
The patients with quiescent CD were enrolled into this study between September 2019 and July 2020. Quiescent CD was defined as a Crohn’s disease activity index (CDAI) ≤ 150 and a C-reactive protein (CRP) level of ≤ 0.3 mg/dL.6 (link),13 (link) The CDAI is a validated standard calculated using the scores for bowel habits, abdominal pain, general condition, Crohn’s disease-associated findings, use of medicines for diarrhea, abdominal mass sensation, hematocrit, and body weight.14 (link) Prior to this study, endoscopic mucosal healing had been confirmed by colonoscopy and/or capsule endoscopy. Since we did not have a validated Japanese version of the Rome IV diagnostic questionnaire, we used a Japanese version of the Rome III diagnostic questionnaire for functional gastrointestinal disorders to evaluate IBS-like symptoms.15 (link) The patients classified as diarrhea-predominant IBS (IBS-D) was included in this study. The patients who completely met the conclusion criteria of both quiescent CD and IBS-D were recruited consecutively. Clinical information and symptoms were evaluated using a self-completed symptom questionnaire.
This study was performed with approval (No. 3158) from the Ethics Committee of Hyogo College of Medicine and registered in the University Hospital Medical Information Network (Registration No. UMIN000041577). Patients who had given fully informed consent were enrolled, and the study was conducted according to the principles governing human research stipulated by the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript.
Tomita T., Fukui H., Morishita D., Maeda A., Makizaki Y., Tanaka Y., Ohno H., Oshima T, & Miwa H. (2023). Diarrhea-predominant Irritable Bowel Syndrome-like Symptoms in Patients With Quiescent Crohn’s Disease: Comprehensive Analysis of Clinical Features and Intestinal Environment Including the Gut Microbiome, Organic Acids, and Intestinal Permeability. Journal of Neurogastroenterology and Motility, 29(1), 102-112.
Publication 2023
Abdomen Abdominal Pain Body Weight Capsule Endoscopy Colonoscopy C Reactive Protein Crohn Disease Defecation Diagnosis Diarrhea Endoscopy Ethics Committees Functional Gastrointestinal Disorders Homo sapiens Japanese Mucous Membrane Patients Pharmaceutical Preparations Volumes, Packed Erythrocyte
5
Identifying IBD Using Hospital Claims Data
This study used claims data from all 19,452 outpatients and inpatients at the Department of Gastroenterology, Tohoku University Hospital, from 1 January 2016 to 31 December 2020. The claims data included the identification number, ICD-10 codes, birth date, sex, visit date, prescription drugs, workups, and procedures. We developed 11 algorithms to identify IBD by combining the ICD-10 codes (CD: K-50, UC: K-51), prescription drugs, and workups (Table 1). Prescription drugs included the following: oral 5-aminosalicylates (mesalazine and salazosulfapyridine), topical medication (5-aminosalicylates and steroids), thiopurine (azathioprine and mercaptopurine), biological medicine (infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab), zentacoart, and elemental diet. Workups included the following: colonoscopy, small bowel series, and capsule endoscopy.
Prescription drugs and workups were determined in accordance with the Japanese guidelines for IBD [22 ]. Oral or injectable steroids and tacrolimus were used for IBD and other diseases; thus, we did not include them with the prescription drugs.
Takahashi S., Obara T., Kakuta Y., Shimoyama Y., Naito T., Moroi R., Kuroha M., Shiga H., Kinouchi Y, & Masamune A. (2022). Validity of Diagnostic Algorithms for Inflammatory Bowel Disease in Japanese Hospital Claims Data. International Journal of Environmental Research and Public Health, 19(13), 7933.
Full text: Click here
Publication 2022
5-Aminosalicylate Adalimumab Azathioprine Biopharmaceuticals Capsule Endoscopy Childbirth Colonoscopy Diet, Elemental golimumab Infliximab Inpatient Intestines, Small Japanese Mercaptopurine Mesalamine Outpatients Pharmaceutical Preparations Prescription Drugs Steroids Sulfasalazine Tacrolimus Ustekinumab vedolizumab

Most recents protocols related to «Capsule Endoscopy»

1
Capsule Endoscopy with Patency Confirmation
Small-bowel patency was confirmed using patency capsules (PC; Medtronic, Minneapolis, MN, USA) in all patients before the CE procedure. The PillCamTMSB3 (Medtronic) was used for all patients. The patient was instructed to ingest the PC at 23:00 (or before going to bed), 2 days before the CE examination. The patient was allowed to take 20 mL of 0.75% sodium picosulfate hydrate and 34 g of magnesium citrate at 21:00 on the day before the CE examination in preparation for the procedure and fasted for 12 h after. At 9:00 on the CE examination day, after confirming small-bowel patency (confirmation of PC excretion without collapse or PC existence in the colon within 30–33 h), the patient ingested the CE with water after drinking dimethicone water. The patient was released after identification of the intestinal villi using a real-time viewer. Drinking water was permitted for 2 h, and a meal was permitted for 4 h after CE ingestion. At 12 h after ingestion, the data recorder was removed, and CE excretion was confirmed visually by the patient. All images were analyzed using the RAPID 8 software (Given Imaging, Dublin, Ireland) by two board-certified physicians of the Japanese Association for Capsule Endoscopy. The LS was incorporated into the RAPID 8 software.
Hiraga H., Chinda D., Hasui K., Murai Y., Maeda T., Higuchi N., Ogasawara K., Kudo S., Sawada Y., Tatsuta T., Kikuchi H., Ebina M., Hiraga N., Mikami T., Sakuraba H, & Fukuda S. (2023). Evaluation of Crohn’s Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α2-Glycoprotein. Diagnostics, 13(4), 626.
Full text: Click here
Publication 2023
Capsule Capsule Endoscopy Colon dimethicone Intestines Intestines, Small Japanese magnesium citrate Patients Physicians picosulfate sodium Shock
2
Capsule Endoscopy and Mucosal Healing in Crohn's Disease
The study included 29 consecutive patients with CD who underwent CE in our department between July 2020 and June 2021. Cases of incomplete CE, in which the cecum was not reached, and inaccessibility of videos due to mechanical errors were excluded from the study. We excluded nine patients without LRG measurements. Finally, 20 patients were included in the study (Figure 1). Table 1 and Table S1 show the patient characteristics. The serum LRG levels were measured in all 20 patients within 2 months and were analyzed by LSI Medience (Tokyo, Japan). CS was performed within 2 months in 12 of the 20 cases. Clinical disease activity was assessed using the CDAI, and clinical remission was defined by an index of <150 [30 (link)]. The Lewis Score (LS) [31 (link)] and Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI) [32 (link)] were used as the CE activity scores. The LS [31 (link)] divides the small bowel into three segments by transit time and assigns scores to endoscopic findings (i.e., mucosal edema, ulcers, and strictures) and characteristics of CD. Scores <135, 135–790, and >790 points indicate normal or MH, mild inflammation, and moderate-to-severe inflammation, respectively. Another score, known as the CECDAI score, divides the small bowel into two segments and includes the degree and extent of mucosal inflammation and the presence of strictures [33 (link)]. Scores <3.5, 3.5–5.8, and >5.8 points indicate normal or MH, mild-to-moderate inflammation, and moderate-to-severe inflammation, respectively. MH in CE was defined as an LS of <135 and CECDAI score <3.5 points. We defined the group that achieved MH in LS and CECDAI as the “CE-MH group” and the group that did not achieve MH as the “CE-non-MH group.” Furthermore, we defined the group that achieved MH within the CS observation range (terminal ileum-rectum) as the “CS-MH group” and the group that did not achieve MH as the “CS-non-MH group.” This study was approved by the Ethics Committee of Hirosaki University Graduate School of Medicine (approval number: 2019-110-1). We obtained written informed consent from all patients (or guardians) before inclusion in this study.
Hiraga H., Chinda D., Hasui K., Murai Y., Maeda T., Higuchi N., Ogasawara K., Kudo S., Sawada Y., Tatsuta T., Kikuchi H., Ebina M., Hiraga N., Mikami T., Sakuraba H, & Fukuda S. (2023). Evaluation of Crohn’s Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α2-Glycoprotein. Diagnostics, 13(4), 626.
Full text: Click here
Publication 2023
Capsule Endoscopy Cecum Crohn Disease Edema Endoscopy Ethics Committees Ileum Inflammation Intestines, Small Legal Guardians Mucositis Mucous Membrane Patients Rectum Serum Stenosis Ulcer
3
Gastrointestinal Bleeding Management in Veterans
A retrospective assessment of veterans presenting with gastrointestinal bleeding found on video capsule endoscopy (VCE) and deep enteroscopy (DE) from January 2006 to December 2018 was reviewed to assess the best strategy for management. Three hundred and twelve symptomatic patients (inpatients and outpatients) were diagnosed with small bowel angiodysplasias (GIADs) via VCE and DE, with or without the Endocuff device. After the initial stabilization of anemias, most of which were non-actively bleeding chronic anemias, and after undergoing upper and lower endoscopies, a video capsule endoscopy (VCE) was obtained. The VCE was frequently done as an outpatient, as most patients were not actively bleeding. The therapies, device-assisted enteroscopy (DAE) or push enteroscopy (PE), ablation, Lanreotide infusions, and iron replacement, were managed in outpatient clinics. Since admissions and re-admissions were difficult to document for just bleeding and not comorbidities, the Charlson Comorbidity Index Score was used to define the health state of each treatment group. Patients were followed prospectively, and data were analyzed retrospectively for treatment effects.
Gutierrez M., Kesavan C., Das A., Jackson C.S, & Strong R.M. (2023). Strategic Management of Bleeding Small Bowel Gastrointestinal Angiodysplasias (GIADs): A 12 Year Retrospective Review in a Veteran Population and Cost Comparison. Diagnostics, 13(3), 525.
Full text: Click here
Publication 2023
Anemia Angiodysplasia Capsule Endoscopy Endoscopy Inpatient Intestines, Small Iron lanreotide Medical Devices Outpatients Patients Veterans
4
Capsule Endoscopy Image Analysis: Evaluating AI and Gastroenterologist Performance
Capsule endoscopic images of 100 patients obtained from the 2 hospitals were used. The patients baseline demographic data were also collected.
The small intestine was divided into 3 sections to facilitate image processing. To extract various images from different sections, 3000 consecutive frames were randomly extracted from each third and produced as a video (Fig. 1). A total of 300 video clips were generated. The video was produced in *.avi format so that it could be played while limiting the speed to < 30 frames per second. Because the images were randomly generated, several CE videos did not move and remained in a fixed position in the small intestine. Hence, to identify how CE stasis affects judgment discrepancies between AI and gastroenterologists, we calculated the pixel-level difference for each video to roughly measure the capsule movement speed.
Five gastrointestinal endoscopy specialists (G5, > 100 capsules read; G1, > 200 capsule read; G2, G3, G4, > 500 capsule read) in South Korea working in high-volume tertiary hospitals analyzed the 300 CE video clip images and evaluated the visible areas. G5 had 2 years, G1 had 5 years, G3 had 10 years, G2 had 15 years, and G4 had 16 years of experience reading CE videos. Based on the ratio of visible area, image quality was classified as 100% to 75% (high), 75% to 50% (middle), or < 50% (low).
The clean mucosal detection range for the 300 videos was also evaluated using the AI algorithm. Depending on the visible area of each frame, the least visible area was assigned a value of 0 and the entire visible area was assigned a value of 1. The average was calculated and assumed to be the result equivalent to the visualization scale (VS; refer to Equation 1 in a previous study[11 (link)]). Additionally, according to the range of the evaluated average visible area for comparison with the gastroenterologists judgment, the results were scored 1.0 to 0.75 (high), 0.75 to 0.50 (middle), and < 0.50 (low).
Ju J., Oh H.S., Lee Y.J., Jung H., Lee J.H., Kang B., Choi S., Kim J.H., Kim K.O, & Chung Y.J. (2023). Clean mucosal area detection of gastroenterologists versus artificial intelligence in small bowel capsule endoscopy. Medicine, 102(6), e32883.
Full text: Click here
Publication 2023
A 300 Capsule Capsule Endoscopy Clip Endoscopy, Gastrointestinal Gastroenterologist Intestines, Small Movement Mucous Membrane Patients Reading Frames Specialists
5
Warfarin Reversal in GI Bleeding
This retrospective study of medical and laboratory records was conducted between January 1, 2015 through December 31, 2020 at the University of Rochester Medical Center and the University of North Carolina Medical Center. Patients taking warfarin that were ≥ 18 years of age with an INR ≥ 2 who presented to the ED with GI bleeding requiring anticoagulation reversal were eligible for inclusion. Only patients managed by 4F-PCC or plasma with or without vitamin K were included in this analysis. Patients who received 3F-PCC or other reversal agents for warfarin reversal, received > 1 dose of 4F-PCC, and/or trauma patients were excluded. Subjects were stratified into two groups according to the warfarin reversal product they received: plasma or 4F-PCC. The collected data included patient demographics, past medical history, medications, date and time of ED admission, transfusion information, results of GI diagnostic procedures, results of laboratory tests, and clinical outcomes. The study was approved by the Research Study Review Board and the Office of Human Research Ethics. All procedures were conducted in compliance with the ethical standards of the responsible institution on human subjects and the Helsinki Declaration.
The GI procedures of interest included endoscopy, colonoscopy, sigmoidoscopy, enteroscopy, cholecystectomy, gastroscopy, capsule endoscopy, and tagged GI bleed scan. The length of time from ED admission to GI procedure, and ED, hospital, and ICU (if applicable) length of stay (LOS) were also calculated. The primary outcome of interest in this study was the time from ED admission to the first diagnostic GI procedure. The secondary outcomes of interest were ED, hospital and ICU (if applicable) LOS. Exploratory outcomes were common comorbidities that were correlated with a shorter time to the diagnostic GI procedure.
The Pearson’s Chi-squared test with Yates’ continuity correction and Wilcoxon rank sum were used for statistical comparison between plasma and 4F-PCC patients. The difference between patients who received plasma and 4F-PCC was estimated for each of the four clinical measures (ED, ICU, and hospital LOS, as well as time to first diagnostic GI procedure), adjusting separately for each of 30 comorbidities or for having any comorbidities. The most common comorbidities include recurrent GI bleeding, hypertension (HTN), cerebrovascular accident (CVA), deep vein thrombosis (DVT), valve disease, A-Fib, coronary artery disease (CAD), and renal failure. The adjusted comparison was done using a Kruskal-Wallis rank sum test between the four groups: 4F-PCC and plasma with and without the comorbidity. P-values < 0.05 were considered statically significant.
Spector H., McRae H.L., Love T., Northam K., Refaai K., Rollins-Raval M.A, & Refaai M.A. (2023). Reduced Time to Procedure for Gastrointestinal Bleeding After Warfarin Reversal With Four-Factor Complex Concentrate as Compared to Plasma. Journal of Clinical Medicine Research, 15(1), 51-57.
Publication 2023
Anticoagulation Reversal Blood Transfusion Capsule Endoscopy Cerebrovascular Accident Cholecystectomy Colonoscopy Coronary Artery Disease Deep Vein Thrombosis Endoscopy Factor IX Complex Gastroscopy High Blood Pressures Homo sapiens Kidney Failure Patients Pharmaceutical Preparations Plasma Proctosigmoidoscopy Radionuclide Imaging Tests, Diagnostic Vitamin K Warfarin Wounds and Injuries

Top products related to «Capsule Endoscopy»

1
Pillcam sb3 by Medtronic
Sourced in United States, Ireland
The PillCam SB3 is a small, single-use video capsule that is swallowed by the patient. It is designed to take images of the small intestine as it passes through the digestive system.
2
Pillcam sb2 by Medtronic
Sourced in United States, Ireland
The Pillcam SB2 is a wireless capsule endoscope designed to visualize the small intestine. It is a single-use, disposable device that is swallowed by the patient and captures images as it passes through the digestive tract. The Pillcam SB2 provides physicians with a minimally invasive tool to diagnose and monitor various gastrointestinal conditions.
3
Patency capsules by Medtronic
Sourced in United States
Patency capsules are a type of medical device used in the gastrointestinal (GI) tract. They are designed to evaluate the patency, or openness, of the GI tract before the administration of other diagnostic or therapeutic procedures. The capsule is swallowed and its passage through the GI tract is monitored, providing information about the integrity and accessibility of the patient's digestive system.
4
Vantage 128 by Verasonics
Sourced in United States
The Vantage 128 is a high-performance ultrasound research platform developed by Verasonics. It features 128 independent transmit and receive channels, enabling advanced ultrasound imaging capabilities. The Vantage 128 provides researchers with the tools to explore new ultrasound techniques and applications.
5
Pillcamtm sb3 by Medtronic
Sourced in United States
The PillcamTM SB3 is a small, wireless capsule endoscope designed for the visualization of the small intestine. It captures high-quality images as it travels through the digestive tract, providing physicians with important information to assist in the diagnosis and management of various gastrointestinal conditions.
6
Spss for window by IBM
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria
SPSS for Windows is a statistical software package developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, analysis, and visualization.
7
Pillcam sb2plus sb3 by Medtronic
Sourced in Japan
The PillCam® SB2plus/SB3 is a small, wireless capsule endoscope developed by Medtronic. The device is designed to capture images of the small intestine as it travels through the gastrointestinal tract. The capsule contains a camera, light source, and transmitter, which send images to a recording device worn by the patient during the examination.
8
Monoclonal mouse anti human cd3 clone f7.2.38 by Agilent Technologies
Sourced in United States
Monoclonal mouse anti-human CD3 (clone F7.2.38) is a laboratory reagent used to detect the presence of CD3, a protein complex found on the surface of mature T cells. This monoclonal antibody is specific to the CD3 antigen and can be used in various immunoassay techniques to identify and quantify T cells.
9
Stata 13 by StataCorp
Sourced in United States, Denmark, United Kingdom, Austria, Sweden
Stata 13 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphical capabilities. Stata 13 is designed to handle complex data structures and offers a variety of statistical methods for researchers and analysts.
10
Sas system for windows by SAS Institute
Sourced in United States, Cameroon, Japan
The SAS System for Windows is a comprehensive software suite for data analysis, management, and reporting. It provides a powerful platform for statistical analysis, data mining, and business intelligence. The SAS System for Windows includes a wide range of tools and functionalities to help users effectively manage and analyze their data.

More about "Capsule Endoscopy"

Capsule endoscopy is a revolutionary non-invasive diagnostic procedure that utilizes a tiny, wireless camera encased in a pill-sized capsule to capture detailed images of the digestive tract.
The patient simply swallows the capsule, and it travels naturally through the esophagus, stomach, and small and large intestines, transmitting the images to a recording device worn by the patient.
This innovative technique allows for the visualization of areas of the gastrointestinal tract that are often difficult to access using traditional endoscopic methods.
Capsule endoscopy has proven to be an invaluable tool in the detection and diagnosis of a variety of conditions, including obscure gastrointestinal bleeding, Crohn's disease, small intestinal tumors, and other disorders.
The procedure is typically well-tolerated by patients and has a low risk of complications.
To optimize your capsule endoscopy research, consider leveraging AI-driven platforms like PubCompare.ai.
This powerful tool can help you easily locate relevant protocols from the literature, pre-prints, and patents, and use its AI-powered comparisons to identify the best protocols and products for your specific needs.
By utilizing PubCompare.ai, you can enhance the reproducibility and accuracy of your capsule endoscopy research, ensuring that your findings are reliable and impactful.
When exploring capsule endoscopy, you may encounter a variety of related terms and technologies, such as the PillCam SB3, Pillcam SB2, Patency capsules, Vantage 128, PillcamTM SB3, SPSS for Windows, PillCam® SB2plus/SB3, Monoclonal mouse anti-human CD3 (clone F7.2.38;, Stata 13, and SAS System for Windows.
Understanding these terms and how they relate to capsule endoscopy can help you navigate this exciting field more effectively.
By leveraging the insights and tools available, you can optimize your capsule endoscopy research, driving advancements in this important diagnostic field and improving patient outcomes.
Embark on your capsule endoscopy journey with confidence and precision, and let PubCompare.ai be your trusted AI-powered companion along the way.